L. Tehrani

发表

[3H]-methoxymethyl-MTEP and [3H]-methoxy-PEPy: potent and selective radioligands for the metabotropic glutamate subtype 5 (mGlu5) receptor.

N. Cosford, M. Varney, Sara P Rao, 2003, Bioorganic & medicinal chemistry letters.

3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity.

Mark Washburn, N. Cosford, L. Bristow, 2003, Journal of medicinal chemistry.

Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity.

N. Cosford, P. Prasit, B. Muñoz, 2004, Journal of medicinal chemistry.

Cyclohexenyl- and dehydropiperidinyl-alkynyl pyridines as potent metabotropic glutamate subtype 5 (mGlu5) receptor antagonists.

N. Cosford, B. Muñoz, Merryl D. Cramer, 2005, Bioorganic & medicinal chemistry letters.

2-(2-[3-(pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl) pyridine: a highly potent, orally active, metabotropic glutamate subtype 5 (mGlu5) receptor antagonist.

Dehua Huang, N. Cosford, Merryl D. Cramer, 2004, Bioorganic & medicinal chemistry letters.

[3H]Methoxymethyl-3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine Binding to Metabotropic Glutamate Receptor Subtype 5 in Rodent Brain: In Vitro and in Vivo Characterization

Nicholas D. P. Cosford, N. Cosford, M. Bradbury, 2002, Journal of Pharmacology and Experimental Therapeutics.

5-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-2,3'-bipyridine: a highly potent, orally active metabotropic glutamate subtype 5 (mGlu5) receptor antagonist with anxiolytic activity.

Dehua Huang, N. Cosford, B. Muñoz, 2004, Bioorganic & medicinal chemistry letters.

Discovery of highly potent, selective, orally bioavailable, metabotropic glutamate subtype 5 (mGlu5) receptor antagonists devoid of cytochrome P450 1A2 inhibitory activity.

Dehua Huang, N. Cosford, Merryl D. Cramer, 2004, Bioorganic & medicinal chemistry letters.

Pyrimidine methyl anilines: selective potentiators for the metabotropic glutamate 2 receptor.

E. Hu, N. Cosford, A. Pinkerton, 2004, Bioorganic & medicinal chemistry letters.

Design and Optimization Leading to an Orally Active TTK Protein Kinase Inhibitor with Robust Single Agent Efficacy.

G. Fenalti, L. LeBrun, Dan Zhu, 2019, Journal of medicinal chemistry.

The design and synthesis of potent and cell-active allosteric dual Akt 1 and 2 inhibitors devoid of hERG activity.

Jun Liang, R. Robinson, S. F. Barnett, 2008, Bioorganic & medicinal chemistry letters.

3-[Substituted]-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitriles: identification of highly potent and selective metabotropic glutamate subtype 5 receptor antagonists.

N. Cosford, Merryl D. Cramer, J. Roppe, 2005, Bioorganic & medicinal chemistry letters.

Substituted xanthines, pteridinediones, and related compounds as potential antiinflammatory agents. Synthesis and biological evaluation of inhibitors of tumor necrosis factor alpha.

H. Cottam, D. Carson, H. Shih, 1996, Journal of medicinal chemistry.

Optimization of a Series of Triazole Containing Mammalian Target of Rapamycin (mTOR) Kinase Inhibitors and the Discovery of CC-115.

P. Worland, D. Mortensen, B. Cathers, 2015, Journal of medicinal chemistry.

Discovery of mammalian target of rapamycin (mTOR) kinase inhibitor CC-223.

P. Worland, D. Mortensen, B. Cathers, 2015, Journal of medicinal chemistry.

The Discovery of a Dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer Initiated from a Phenotypic Screen.

L. LeBrun, Dan Zhu, B. Pagarigan, 2017, Journal of medicinal chemistry.

Cyclohexenyl- and dehydropiperidinyl-alkynyl pyridines as potent metabotropic glutamate subtype 5 (mGlu5) receptor antagonists.

N. Cosford, B. Muñoz, Merryl D. Cramer, 2005, Bioorganic & medicinal chemistry letters.

The Behavioral Profile of the Potent and Selective mGlu5 Receptor Antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) in Rodent Models of Anxiety

N. Cosford, L. Bristow, Jeffery J. Anderson, 2004, Neuropsychopharmacology.

Metabotropic Glutamate Receptor mGlu5 Is a Mediator of Appetite and Energy Balance in Rats and Mice

N. Cosford, M. Bradbury, U. Campbell, 2005, Journal of Pharmacology and Experimental Therapeutics.

Metabotropic Glutamate Receptor mGlu 5 Is a Mediator of Appetite and Energy Balance in Rats and Mice

N. Cosford, M. Bradbury, U. Campbell, 2004 .

Discovery and optimization of thieno[2,3-d]pyrimidines as B-Raf inhibitors.

B. Cathers, S. Sakata, J. Leisten, 2012, Bioorganic & medicinal chemistry letters.

A Novel Triazolopyridine-Based Spleen Tyrosine Kinase Inhibitor That Arrests Joint Inflammation

K. Miyazawa, B. Bennett, L. LeBrun, 2016, PloS one.

Structure-Guided Optimization Provides a Series of TTK Protein Inhibitors with Potent Antitumor Activity.

L. LeBrun, T. Tran, K. Leftheris, 2021, Journal of medicinal chemistry.

Optimization of a Series of Triazole Containing Mammalian Target of Rapamycin (mTOR) Kinase Inhibitors and the Discovery of CC-115.

P. Worland, D. Mortensen, B. Cathers, 2015, Journal of medicinal chemistry.

Synthesis and physicochemical characterization of the lanthionine analog of somatostatin[1–14]

G. Melacini, M. Goodman, G. Ösapay, 1994, Letters in Peptide Science.

2‐{2‐[3‐(Pyridin‐3‐yloxy)phenyl]‐2H‐tetrazol‐5‐yl}pyridine: A Highly Potent, Orally Active, Metabotropic Glutamate Subtype 5 (mGlu5) Receptor Antagonist.

N. Cosford, Merryl D. Cramer, J. Roppe, 2005 .

Design and Synthesis of Novel Cereblon Binders for Use in Targeted Protein Degradation.

D. Mortensen, L. Tehrani, Dehua Huang, 2023, Journal of medicinal chemistry.